Global enterprises join Talogy to rethink High Potential talent at SIOP Conference 2026

Global enterprises join Talogy to rethink High Potential talent at SIOP Conference 2026

Research paper on GenAI use another key highlight during four-day event PITTSBURGH, June 3, 2026 /PRNewswire/ -- Global talent management solutions specialist, Talogy, delivered a landmark session designed to rewrite the rules for high-potential...

CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia

CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia

DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development and regulatory approvals, including FDA IDE and PMA pathways Full-scale entry into North...

Johnson & Johnson Launches 'Gut Tunnel' Experience in Singapore to Highlight the Importance of Endoscopic Remission in IBD

Johnson & Johnson Launches 'Gut Tunnel' Experience in Singapore to Highlight the Importance of Endoscopic Remission in IBD

New data presented at Digestive Disease Week 2026 reinforces endoscopic remission as being associated with long-term patient outcomes, [1] , [2] yet more than 60% of people with IBD have not heard of this key treatment goal. [3] , [4] Anchoring...

Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and...

The Future of Surgical Robotics: Exploring Advanced Supply Chains and Manufacturing at 2026 Medtec

The Future of Surgical Robotics: Exploring Advanced Supply Chains and Manufacturing at 2026 Medtec

SHANGHAI, May 12, 2026 /PRNewswire/ -- In 2026, the surgical robotics industry continues to grow steadily. Recent reports show that both procedure volumes and system deployments are rising consistently. Intuitive Surgical surpassed expectations in...

AmChamSG Announces 2026-7 Chair and Board of Governors

AmChamSG Announces 2026-7 Chair and Board of Governors

Demonstrating leadership in board diversity with women governors occupying at least 50% of seats since 2021 SINGAPORE, April 30, 2026 /PRNewswire/ -- Adam Click, Regional Client Lead, Google Asia Pacific, has been elected Chair of The American...

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading...

GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer

GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer

SEOUL, South Korea, March 20, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant...

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia

The brand also expands daily disposable options for astigmatic adults with the launch of ACUVUE® OASYS MAX 1-Day for ASTIGMATISM, bringing pioneering innovation that delivers visual clarity and comfort [+],[**],[2],[3] as vision needs evolve....

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative...

  • 1
  • 2
  • 3
  • menu
    menu